A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Claims checked

  • Tendon and muscle injuries heal faster

    Not studied

    Recovery & healing · Patients: tendon, ligament and muscle injuries · Animal study

    Better tendon healing in rats [3] and favorable effects on tendon cells in cell culture [4][5]. There is no study on tissue healing in humans; the systematic review found only three uncontrolled studies without a healing endpoint [13].[4][5]

  • Gut and stomach heal faster

    Not studied

    Recovery & healing · Patients: inflammatory bowel disease · Animal study

    Fistula and wound healing in the intestine in rats, including after administration in drinking water [7]. Early clinical trials in bowel disease are mentioned by the developer group [8], results are not published [1]; a registered phase I study reported no results [14].

  • Less joint pain

    Single unconfirmed finding

    Recovery & healing · Patients: knee pain of various causes · Human, non-randomised small studiesEvery study behind this level and result had fewer than 100 participants. Small studies report larger effects on average than large ones, so the result is less certain.

    In a retrospective telephone survey, 14 of 16 people reported less knee pain after injection into the joint, four of them additionally with thymosin β4; no control group, no validated instruments [10]. Very low trustworthiness according to the systematic review [13].

small studies: Every study behind this level and result had fewer than 100 participants. Small studies report larger effects on average than large ones, so the result is less certain.

Mechanism of action

Evidence map: BPC-157

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

According to the developer group, BPC-157 (sequence GEPPPGKPADDAGLV) is the synthetic partial sequence of a protein from human gastric juice. The name comes from a screening program at the University of Zagreb in the early 1990s; according to a 2026 review, more than 80% of all publications come from this one research group, and independent replications are rare [1]. A US doping laboratory first found the peptide in confiscated vials [2]. In rats with a transected Achilles tendon, the tendons healed with greater load-bearing capacity under BPC-157, and the animals walked better [3]. An independent group from Taiwan confirmed parts of this in cell culture: BPC-157 accelerated outgrowth of tendon fibroblasts, their migration (via the FAK-paxillin pathway) and their survival under oxidative stress, without directly increasing cell division [4]; it also increased expression of the growth hormone receptor in these cells [5].

The best-described mechanism is the formation of new blood vessels. In endothelial cells, BPC-157 increased the amount of VEGF receptor 2 (but not of VEGF-A), promoted its uptake into the cell and activated the VEGFR2-Akt-eNOS pathway; in rats with a clamped leg artery, blood flow recovered faster [6]. In the gastrointestinal tract, the data again come almost entirely from Zagreb: in rats, intestinal-cutaneous fistulas healed better with BPC-157, including when given in drinking water, and the effect persisted when nitric oxide formation was inhibited [7]. The developer group describes early clinical trials in inflammatory bowel disease under the codes PL-10, PLD-116 and PL 14736 (company Pliva) as safe [8]; published results of these trials were not found, and phase II or phase III studies did not follow [1].

The only formal pharmacokinetic study comes from China: in rats and dogs, the half-life was under 30 minutes, after intramuscular injection 14–19% (rat) and 45–51% (dog) reached the bloodstream, and the peptide rapidly broke down into fragments and amino acids [9]. In humans, there are three small studies from the same research group, conducted in private practices: a retrospective telephone survey after injections into the knee joint [10], an uncontrolled pilot study in bladder pain syndrome [11] and a safety test with infusion in two people [12]. A 2026 systematic review rated the trustworthiness of these data as very low [13]. A phase I study with tablets registered in 2015 has to date reported no completion and no results [14]. BPC-157 is prohibited in sport [15].

Targets

TargetTypeActionKey dataEvidence
VEGF receptor 2 (VEGFR2)ReceptorExpression ↑ Animal study[6]
Endothelial NO synthase (eNOS) via VEGFR2-AktEnzymeActivator Laboratory[6]
FAK-paxillin pathway (tendon fibroblasts)Signaling pathwayActivator Laboratory[4]
Growth hormone receptor (tendon fibroblasts)ReceptorExpression ↑ Laboratory[5]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamineno data
  • Noradrenalineno data
  • Serotoninno data
  • Acetylcholineno data
  • Glutamate · AMPAno data
  • Glutamate · NMDAno data
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophinsno data
  • Blood flow↑ · New vessel formation in the chicken egg assay and in cell culture; faster recovery of blood flow after arterial occlusion (rat)[6]
  • Nitric oxide↑ · activates eNOS in endothelial cells; fistula healing in the rat persisted despite NO inhibition[6][7]
  • Energy metabolismno data
  • Insulin · glucoseno data
  • Inflammation · oxidative↓ · fewer granulocytes in the tendon defect (rat); better survival of tendon cells under hydrogen peroxide (cell culture)[3][4]
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Routes of administration and bioavailability

How much of a compound reaches the blood or target tissue depends on the route into the body and on the dosage form. All routes of administration explained

  • Intramuscular · Solution

    14–19% (rat), 45–51% (dog)

    Rapid uptake, half-life under 30 minutes, no longer detectable after 4 hours [9].

    Animal study

  • Oral (swallowed) · Drinking water (animal), tablet (study without results)

    According to the developer group, stable in gastric juice; in rats it was effective in the intestinal model also via drinking water [7]. Whether this is a local effect in the gut or an effect after uptake into the blood is open; oral bioavailability was not measured in any species [1]. A phase I study with tablets reported no results [14].

    Animal study

  • Subcutaneous (under the skin) · Solution

    The most common route online, but not pharmacokinetically characterized in any study [1].

    No data

  • Intravenous · Infusion

    100% (by definition)

    In rats, half-life under 30 minutes [9]; in humans, only a safety test in two people without published concentration measurements [12].

    Human, non-randomised

Human studies

  • Injection into the knee joint for knee pain

    retrospective chart review with telephone survey, no control group · Patients: knee pain of various causes · n = 16 · Follow-up usually 6–12 months after the injection

    Measured: self-assessed pain relief, no validated scales

    Result: 11 of 12 with BPC-157 alone and 3 of 4 with additional thymosin β4 reported marked improvement.[10]

    Human, non-randomised

  • Injection into the bladder wall for bladder pain syndrome

    uncontrolled pilot study · Patients: women with interstitial cystitis not responding to pentosan polysulfate · n = 12 · single treatment

    Measured: Global Response Assessment

    Result: 10 of 12 reported complete and 2 reported substantial improvement; no side effects reported. Without a control group, not distinguishable from placebo or spontaneous course.[11]

    Human, non-randomised

  • Safety of an infusion

    uncontrolled pilot study · healthy (two people, both previously treated with BPC-157) · n = 2 · two infusions on two days

    Measured: Laboratory values (heart, liver, kidney, thyroid, blood glucose), vital signs, side effects

    Result: No measurable changes and no side effects; informative value minimal because of n = 2.[12]

    Human, non-randomised

Risks and warnings

  • Lack of safety data in humans

    Only three uncontrolled studies with a total of 30 people, all without reported side effects, but methodologically weak [13]. Standard tests for genetic damage (Ames test, chromosomal aberration) are lacking; this is not an indication of a risk, but a gap [1].

    Human, non-randomised

  • Unclear identity and purity

    BPC-157 was first identified in confiscated vials [2]. There is no tested pharmaceutical preparation, and none of the human studies used standardized products [1].

    No data

  • Theoretical: promotion of tumor vessels

    BPC-157 activates VEGF receptor 2 and promotes new vessel formation [6]. A review sees a theoretical risk in this for undetected tumors; there are no data on this from animal experiments or from humans [1].

    No data

  • Doping

    On the 2025 WADA Prohibited List under S0 [15]; detection methods in urine have been developed [2].

    No data

Fact check: common claims

  • not supported

    “BPC-157 heals tendons, ligaments and muscles”

    Shown only in rats and in cell culture [3][4][5]; in humans there is no study with healing as an endpoint [13].

  • partly supported

    “Hundreds of studies prove the effect”

    The number of animal studies is large, but over 80% come from one research group [1]. In humans there are only three uncontrolled studies with 30 people [13].

  • not supported

    “BPC-157 is endogenous and therefore safe”

    It is a synthetic peptide that, according to the developer group, corresponds to a partial sequence from gastric juice [1]. Safety does not follow from this; systematic safety data in humans are lacking [13].

  • partly supported

    “BPC-157 also works as a capsule because it is stable in gastric juice”

    In rats it was effective in the intestinal model also via drinking water [7]; whether it reaches the blood in humans after swallowing has never been measured [1].

Pharmacokinetics

Absorption
Animal experiments with administration into the abdominal cavity, muscle, drinking water or locally; in humans, only joint, bladder wall and infusion administration in uncontrolled studies [7][9][10][11][12].
Half-life
Under 30 minutes in rat and dog [9]; not validly determined in humans [1].
Metabolism
Rapid breakdown into small peptide fragments and amino acids, excretion via urine and bile (rat, dog) [9]; in plasma, a stable breakdown product forms in vitro that is said to be detectable in urine [2].
Entry into the brain
Not studied.

Legal status

Germany
No marketing authorization known; not checked in medicines registers.
EU
No marketing authorization known; according to a review, the documentation that would be needed for a clinical trial under EMA requirements is lacking [1].
USA
Not approved by the FDA. In April 2026, BPC-157 was removed from Category 2 of the bulk drug substances used in compounding because the nominations were withdrawn; this is not a decision on safety or efficacy [1].
Other countries
Sport: expressly named on the 2025 Prohibited List of the World Anti-Doping Agency (WADA) under S0 (non-approved substances) [15].

Related compounds

TB-500same class

Open questions

  • Can the healing effects be replicated in blinded animal studies by independent laboratories?
  • How does BPC-157 act in randomized, placebo-controlled studies in humans, and is it safe in them?
  • How does the short half-life of under 30 minutes fit with the long-lasting effects in animal experiments?
  • Does activation of VEGF receptor 2 promote the growth of existing tumors?

References

  1. Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625 · PubMed
  2. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490–8. doi:10.1002/dta.2152 · PubMed
  3. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–83. doi:10.1016/S0736-0266(03)00110-4 · PubMed
  4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774–80. doi:10.1152/japplphysiol.00945.2010 · PubMed
  5. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–77. doi:10.3390/molecules191119066 · PubMed
  6. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–33. doi:10.1007/s00109-016-1488-y · PubMed
  7. Klicek R, Sever M, Radic B, Drmic D, Kocman I, Zoricic I, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7–17. doi:10.1254/jphs.fp0072161 · PubMed
  8. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214–21. doi:10.1007/s10787-006-1531-7 · PubMed
  9. He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182 · PubMed
  10. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PubMed
  11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–7. PubMed
  12. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–4. PubMed
  13. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). doi:10.52628/92.3.15837 · PubMed
  14. PharmaCotherapia d.o.o. PCO-02 – Safety and pharmacokinetics trial. ClinicalTrials.gov Identifier: NCT02637284. Registriert 2015, Status unbekannt [abgerufen am 23.10.2026]. NCT02637284
  15. Thevis M, Kuuranne T, Geyer H. Annual banned-substance review 18th edition – analytical approaches in human sports drug testing 2024/2025. Drug Test Anal. 2026;18(4):458–82. doi:10.1002/dta.70033 · PubMed
How this profile was checked

Last reviewed: 2026-10-23. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-23); translation checked on 2026-10-26.

Checked

  • All DOIs via Crossref, all PMIDs via PubMed; three papers from Altern Ther Health Med without a DOI, via PMID only.
  • Key figures checked against abstracts: sequence and confiscated vials [2]; rat Achilles tendon [3]; FAK-paxillin, no direct proliferation effect, H2O2 [4]; GH receptor [5]; VEGFR2 without VEGF-A, Akt-eNOS, hindlimb ischemia [6]; fistula, drinking water, L-NAME [7]; t1/2 under 30 min, i.m. bioavailability 14–19% and 45–51%, urine and bile [9]; knee 16 respondents, 11/12 and 3/4 [10]; 12 women, 10 complete, 2 improved by 80% [11]; two people, both pretreated [12]; three studies, n = 30, very low trustworthiness [13].
  • In the full text [1]: over 80% of the studies from Zagreb; no phase II/III studies after PL 14736; no Ames or chromosome tests; theoretical tumor risk; no standardized products in human studies; removal from FDA Category 2 in April 2026.
  • In the full text [15], Table 1: BPC-157 as an example under S0 of the 2025 WADA Prohibited List; likewise in the 17th edition (2023 list).
  • ClinicalTrials.gov (October 23, 2026): NCT02637284 (phase I, oral tablets, status unknown since 2015, no results); NCT07803250 (rotator cuff, phase I, not yet recruiting); NCT07437547 (hamstring strain, phase II, Hudson Biotech) – see not verified; NCT07752381 (peptide gummies, manufacturer Parlay Wellness, no results) not used.
  • Precision flags (m004; rules in the guideline October 26, 2026; participant numbers, direction and funding checked on October 26, 2026 via PubMed efetch against the abstract, conflict-of-interest statement and affiliations): “Less joint pain”: “kleine_studien” – [10] 17 patients, 16 surveyed ([13] review).

Not verified

  • The review [1] states that WADA listed BPC-157 temporarily in 2022 and later withdrew this. This contradicts the anti-doping overview [15], which lists BPC-157 under S0 in the 2025 list; the withdrawal was not adopted. The current 2026 list was not checked directly.
  • Registry entry NCT07437547 (Hudson Biotech) not used: an entry created at the same time by the same sponsor on TB-500 (NCT07487363) describes itself in the brief summary as a fictitious example; its authenticity is therefore doubtful.
  • Results of the early Pliva trials (PL-10, PLD-116, PL 14736) not found in PubMed; only the developer group's statement that they were safe.
  • The natural origin (protein from gastric juice) rests on statements by the developer group; an independent characterization of the parent protein was not found.
  • Conflicts of interest and funding of the three human studies [10][11][12] are not stated in the abstracts; full texts not freely available.
  • Authorization status in Germany and the EU not checked in registers.

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.